Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection, the expertise of a Scientific Affairs Group, which comprises more than 300 leading KOLs and an uninterrupted funding flow to minimise the time it takes to advance lead products through clinical trials and reach patients.